Cardiometabolic risk indicators that distinguish adults with psychosis from the general population, by age and gender

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Foley, Debra L ^a   Mackinnon, Andrew ^a   Watts, Gerald F ^b   Shaw, Jonathan E ^c   Magliano, Dianna J ^c   Castle, David J ^d   McGrath, John J ^e   Waterreus, Anna ^b   Morgan, Vera A ^b   Galletly, Cherrie A ^f  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e UNIVERSITY OF QUEENSLAND   (Australia)

^f Ramsay Health Care   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; TRIACYLGLYCEROL;

ADULT; AGE DISTRIBUTION; ARTICLE; AUSTRALIAN; BLOOD PRESSURE; BODY MASS; CARDIOMETABOLIC RISK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CHOLESTEROL BLOOD LEVEL; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DIET RESTRICTION; DISEASE ASSOCIATION; DYSLIPIDEMIA; ETHNIC GROUP; FEMALE; GENETIC HETEROGENEITY; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; OBESITY; POPULATION; POPULATION RESEARCH; PSYCHOSIS; SEX DIFFERENCE; SYSTOLIC BLOOD PRESSURE; TREND STUDY; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

ADOLESCENT; ADULT; AUSTRALIA; BLOOD GLUCOSE; BODY MASS INDEX; CHOLESTEROL, HDL; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; OBESITY; PSYCHOTIC DISORDERS; TRIGLYCERIDES; WAIST CIRCUMFERENCE; YOUNG ADULT;

EID: 84893182964     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0082606     Document Type: Article

References (40)

1. Saha S, Chant D, McGrath J (2007) A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch Gen Psychiatry 64: 1123-1131. (Pubitemid 47529346)
2. Laursen TM, Munk-Olsen T, Vestergaard M (2012) Life expectancy and cardiovascular mortality in persons with schizophrenia. Curr Opin Psychiatry 25: 83-88.
3. Bushe CJ, Taylor M, Haukka J (2010) Mortality in schizophrenia: a measurable clinical endpoint. J Psychopharmacol 24[Suppl]: 17-25.
4. Foley DL, Morley KI (2011) Systematic review of early cardiometabolic outcomes of the first treated episode of psychosis. Arch Gen Psychiatry 68: 609-616.
5. Johnson AM, Olefsky JM (2013) The origins and drivers of insulin resistance. Cell 152: 673-684.
6. Yusuf S, Hawken S, Ounpuu S, Bautista L, Franzosi MG, et al INTERHEART Study Investigators (2005) Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study. Lancet 366: 1640- 1649.
7. Roberts LW, Warner TD, Brody JL (2000) Perspectives of patients with schizophrenia and psychiatrists regarding ethically important aspects of research participation. Am J Psychiatry 157: 67-74. (Pubitemid 30027423)
8. Moser DJ, Schultz SK, Arndt S, Benjamin ML, Fleming FW, et al (2002) Capacity to Provide Informed Consent for Participation in Schizophrenia and HIV Research Am J Psychiatry 159: 1201-1207 (Pubitemid 34743262)
9. Morgan VA, Waterreus A, Jablensky A, Mackinnon A, McGrath JJ, et al (2012) People living with psychotic illness in 2010: The second Australian national survey of psychosis. Aust N Z J Psychiatry 46: 735-752.
10. World Health Organization (2008) ICD-10: International statistical classification of diseases and related health problems (10th Rev. Ed.). Geneva: World Health Organization
11. Dunstan DW, Zimmet PZ, Welborn TA, Cameron AJ, Shaw J, et al (2002) Australian Diabetes, Obesity and Lifestyle Study (AusDiab). The Australian Diabetes, Obesity and Lifestyle Study (AusDiab)-methods and response rates. Diabetes Res Clin Pract 57: 119-129. (Pubitemid 34626451)
12. Castle DJ, Jablensky A, McGrath JJ, Carr V, Morgan V, et al (2006) The diagnostic interview for psychoses (DIP): development, reliability and applications. Psychol Med 36: 69-80. (Pubitemid 41825347)
13. AusDiab Report 2000 - Baker IDI. Available: http://www.bakeridi.edu.au/ Assets/Files/AusDiab-Report-2000.pdf Accessed 2013 Nov 18.
14. Survey of High Impact Psychosis. Available: http://www.psychiatry.uwa. edu.au/research/neru/survey/researchers Accessed 2013 Nov 18.
15. Newson R (2000) B splines and splines parameterized by their values at reference points on the X axis. Stata Technical Bulletin 57: 20-27.
16. Holm S (1979) A simple sequentially rejective multiple test procedure. Scandinavian Journal of Statistics 6: 65-70.
17. DeFronzo RA, Ferrannini E (1991) Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 14: 173-194.
18. Morrish NJ, Wang SL, Stevens LK, Fuller JH, Keen H (2001) Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia 44: S14-21. (Pubitemid 32844108)
19. Daumit GL, Dickerson FB, Wang NY, Dalcin A, Jerome GJ, et al (2013) A behavioral weight-loss intervention in persons with serious mental illness. N Engl J Med 368: 1594-1602.
20. Albaugh VL, Singareddy R, Mauger D, Lynch CJ (2011) A double blind, placebo-controlled, randomized crossover study of the acute metabolic effects of olanzapine in healthy volunteers. PLoS One 6: e22662.
21. Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y; EUFEST study group (2008) Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 371: 1085-1097. (Pubitemid 351418005)
22. Nielsen J, Skadhede S, Correll CU (2010) Antipsychotics associated with the development of type 2 diabetes in antipsychotic-naïve schizophrenia patients. Neuropsychopharmacology 35: 1997-2004.
23. Rouillon F, Sorbara F (2005) Schizophrenia and diabetes: epidemiological data. Eur Psychiatry 20: S345-s348. (Pubitemid 43188781)
24. Cohen D, De Hert M (2011) Endogenic and iatrogenic diabetes mellitus in drug-naïve schizophrenia: the role of olanzapine and its place in the psychopharmacological treatment algorithm. Neuropsychopharmacology 36: 2368-2369.
25. Ryan MC, Collins P, Thakore JH (2003) Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry 160: 284- 289.
26. Spelman L, Walsh PI, Sharifi N, Collins P, Thakore JH (2007) Impaired glucose tolerance in first episode drug naive patients with schizophrenia. Diabet Med 24: 481-485. (Pubitemid 46669314)
27. DeFronzo RA, Abdul-Ghani M (2011) Assessment and treatment of cardiovascular risk in prediabetes: impaired glucose tolerance and impaired fasting glucose. Am J Cardiol 108: 3B-24B.
28. Newcomer JW (2007) Antipsychotic medications: metabolic and cardiovascular risk. J Clin Psychiatry (Suppl 4): 8-13.
29. Remington G, Kapur S, Zipursky RB (1998) Pharmacotherapy of first-episode schizophrenia. Br J Psychiatry Suppl; 172: 66-70. (Pubitemid 28258901)
30. Tauscher J, Kapur S (2001) Choosing the right dose of antipsychotics in schizophrenia: lessons from neuroimaging studies. CNS Drugs 15: 671-678. (Pubitemid 33701934)
31. Remington G, Kapur S (2010) Antipsychotic dosing: how much but also how often? Schizophr Bull 36: 900-903.
32. Remington G, Seeman P, Feingold A, Mann S, Shammi C, et al (2011) "Extended" antipsychotic dosing in the maintenance treatment of schizophrenia: a double-blind, placebo-controlled trial. J Clin Psychiatry 72: 1042-1048.
33. Stroup TS, McEvoy JP, Ring KD, Hamer RH, LaVange LM, et al Schizophrenia Trials Network. (2011) A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP). Am J Psychiatry 168: 947-956.
34. De Hert M, Vancampfort D, Correll CU, Mercken V, Peuskens J, et al (2011) Guidelines for screening and monitoring of cardiometabolic risk in schizophrenia: systematic evaluation. Br J Psychiatry 199: 99-105.
35. Mitchell AJ, Delaffon V, Vancampfort D, Correll CU, De Hert M (2012) Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: systematic review and meta-analysis of screening practices. Psychol Med 42: 125-147.
36. De Hert M, Detraux J, van Winkel R, Yu W, Correll CU (2011) Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol 8: 114-126.
37. Thornicroft G (2011) Physical health disparities and mental illness: the scandal of premature mortality. Br J Psychiatry 199: 441-442.
38. International physical health in youth stream (iphYs): Healthy Active Lives (HeAL) statement website. Available: http://www.iphys.org.au/media/HeAL- declaration.pdf Accessed 2013 Nov 18.
39. Galletly CA, Foley DL, Waterreus A, Watts GF, Castle DJ, et al (2012) Cardiometabolic risk factors in people with psychotic disorders: the second Australian national survey of psychosis. Aust N Z J Psychiatry 46: 753-761.
40. Polymeropoulos MH, Licamele L, Volpi S, Mack K, Mitkus SN, et al (2009) Common effect of antipsychotics on the biosynthesis and regulation of fatty acids and cholesterol supports a key role of lipid homeostasis in schizophrenia. Schizophr Res 108: 134-142.